Report Highlights
-
The global cardiovascular therapeutic drug market was worth $140.7 billion in 2009, and is expected to grow by a compound annual growth rate (CAGR) of 2.7% to $144.5 billion in 2010. This market will experience a sizable reduction in the early portion of the forecast period, and then slowly rise to reach $139.8 billion in 2015, a CAGR of -0.7%.
-
The hypertension segment recorded $64.9 billion in sales in 2009. By a large margin, hypertension is the largest segment within the cardiovascular market, driven by a large number of billion-dollar-plus therapies. The market is expected to grow to $65.3 billion in 2010 and experience a reduction through 2015 to $53.7 billion, a compound annual growth rate (CAGR) of -3.9%.
-
Treatment for hyperlipidemia recorded sales of more than $33 billion in 2009. Large therapeutic drugs including Lipitor and Crestor comprise a high concentration of this segment. Driven by patent expirations for Lipitor, and other drugs within this segment, the segment will shrink to about $26 billion by 2015, a CAGR of -4.3%.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This study provides a comprehensive analysis of cardiovascular therapies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the cardiovascular segment. Individual products are forecast on a global basis, as are overall segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.
- Established companies in the industry will benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D.
- Emerging biotechnology players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their therapeutic drug as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study.
- Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry, in a product and company specific analysis.
- Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.
ANALYST CREDENTIALS
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development.
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
Report Highlights
- Worldwide sales of cardiovascular drugs approached $47 billion in 1999, and the leading 15 products in the class generated sales of approximately $18 billion. Cardiovascular drugs discussed in this report comprise adrenergic inhibitors, adrenergic stimulators, angiotensin converting enzyme (ACE) inhibitors, angiotensin II inhibitors, antithrombics, beta blockers, calcium channel blockers, diuretics, steroids and steroidal glycosides, vasodilators, vasopressors, and others.
- Market applications reviewed in this report include acute coronary syndrome, angina, arrhythmia, atherosclerosis, congestive heart failure, coronary artery disease, deep vein thrombosis, edema, hypercholesterolemia, hypertension, hypotension, myocardial infarction and stroke.
- Angiotension II inhibitors, which are indicated for the treatment of heart failure and hypertension, are projected to see an average annual growth of nearly 20% and the antithrombic category will see growth approaching 16% throughout the forecast period (2000-2005).
Related Reports
Recent Reports
Excipients in Pharmaceuticals: Global Markets to 2029
The global market for pharmaceutical excipients was valued at $9.2 billion in 2023. It is expected to grow from $9.7 billion in 2024 to $12.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2029.
Antibody-Drug Conjugates: Technologies and Global Markets
The global market for antibody-drug conjugates is estimated to increase from $10.8 billion in 2023 to reach $47.0 billion by 2029, at a compound annual growth rate (CAGR) of 28.4% from 2024 through 2029.
Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging
The global market for contract pharmaceutical manufacturing, research and packaging is estimated to increase from $212.2 billion in 2023 to reach $310.2 billion by 2029, at a compound annual growth rate (CAGR) of 6.7% from 2024 through 2029.
Global Markets for Drug-Device Combinations
The global market for drug-device combinations is expected to grow from $129.4 billion in 2024 and is projected to reach $199.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 9.1% during the forecast period of 2024 to 2029.
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Top Trending Reports
Global Artificial Intelligence (AI) Market: Investments vs Potential
The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.
Artificial Intelligence (AI) in Life Sciences Market
The global market for artificial intelligence (AI) in life sciences products was valued at $8.0 billion in 2023. The market is estimated to grow from $9.8 billion in 2024 to $33.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.9% from 2024 to 2029.
Drug Discovery Technologies
The global market for drug discovery technologies is expected to grow from $111.9 billion in 2024 and is projected to reach $197.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.0% during the forecast period of 2024 to 2029.
Synthetic Biology: Global Markets
The global market for synthetic biology products was valued at $15.4 billion in 2023. The market is projected to grow from $19.3 billion in 2024 to $61.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 26.1% from 2024 through 2029.
Electric Vehicles and Fuel Cell Vehicles: Global Markets
The global market for electric vehicles and fuel cell vehicles was valued at $655.9 billion in 2023. The market is expected to grow from $758.0 billion in 2024 to $1.8 trillion by 2029, at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More